HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.

Abstract
Tumor-mediated procoagulatory activity leads to venous thromboembolism and supports metastasis in cancer patients. A prerequisite for metastasis formation is the interaction of cancer cells with endothelial cells (ECs) followed by their extravasation. Although it is known that activation of ECs and the release of the procoagulatory protein von Willebrand factor (VWF) is essential for malignancy, the underlying mechanisms remain poorly understood. We hypothesized that VWF fibers in tumor vessels promote tumor-associated thromboembolism and metastasis. Using in vitro settings, mouse models, and human tumor samples, we showed that melanoma cells activate ECs followed by the luminal release of VWF fibers and platelet aggregation in tumor microvessels. Analysis of human blood samples and tumor tissue revealed that a promoted VWF release combined with a local inhibition of proteolytic activity and protein expression of ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type I repeats 13) accounts for this procoagulatory milieu. Blocking endothelial cell activation by the low-molecular-weight heparin tinzaparin was accompanied by a lack of VWF networks and inhibited tumor progression in a transgenic mouse model. Our findings implicate a mechanism wherein tumor-derived vascular endothelial growth factor-A (VEGF-A) promotes tumor progression and angiogenesis. Thus, targeting EC activation envisions new therapeutic strategies attenuating tumor-related angiogenesis and coagulation.
AuthorsAlexander T Bauer, Jan Suckau, Kathrin Frank, Anna Desch, Lukas Goertz, Andreas H Wagner, Markus Hecker, Tobias Goerge, Ludmila Umansky, Philipp Beckhove, Jochen Utikal, Christian Gorzelanny, Nancy Diaz-Valdes, Viktor Umansky, Stefan W Schneider
JournalBlood (Blood) Vol. 125 Issue 20 Pg. 3153-63 (May 14 2015) ISSN: 1528-0020 [Electronic] United States
PMID25977583 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 by The American Society of Hematology.
Chemical References
  • Fibrinolytic Agents
  • Heparin, Low-Molecular-Weight
  • Vascular Endothelial Growth Factor A
  • von Willebrand Factor
  • Tinzaparin
  • Proto-Oncogene Proteins c-ret
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
Topics
  • ADAM Proteins (blood, metabolism)
  • ADAMTS13 Protein
  • Animals
  • Blood Coagulation
  • Blood Platelets
  • Disease Models, Animal
  • Disease Progression
  • Endothelial Cells (metabolism)
  • Enzyme Activation
  • Fibrinolytic Agents (pharmacology)
  • Heparin, Low-Molecular-Weight (pharmacology)
  • Humans
  • Melanoma (blood, metabolism, pathology)
  • Mice
  • Mice, Transgenic
  • Microvessels (metabolism)
  • Neovascularization, Pathologic (metabolism)
  • Platelet Aggregation
  • Protein Binding
  • Proto-Oncogene Proteins c-ret (metabolism)
  • Tinzaparin
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors, metabolism)
  • von Willebrand Factor (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: